Targeting oncogenic mutant p53 for cancer therapy
Frontiers in Oncology, 2015 Among genetic alterations in human cancers, mutations in the tumor suppressor p53 gene are the most common, occurring in over 50% of human cancers. The majority of p53 mutations are missense mutations and result in the accumulation of dysfunctional p53 ...
Tomoo eIwakuma, Alejandro eParrales
doaj +1 more source
Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb. [PDF]
, 2004 Currently available prognostic tools appear unable to adequately predict recurrence and progression in non muscle-invasive bladder carcinomas. We aimed to assess the prognostic value of immunohistochemical evaluation of the cell cycle markers p53, p16 ...
S Jordan +11 more
core +1 more source
Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes [PDF]
, 2012 Mutations in the TP53 gene are very common in human cancers, and are associated with poor clinical outcome. Transgenic mouse models lacking the Trp53 gene or that express mutant Trp53 transgenes produce tumours with malignant features in many organs.
Miquel Taron +64 more
core +1 more source
Models incorporating chromatin modification data identify functionally important p53 binding sites [PDF]
, 2013 Genome-wide prediction of transcription factor binding sites is notoriously difficult. We have developed and applied a logistic regression approach for prediction of binding sites for the p53 transcription factor that incorporates sequence information ...
Barker, Daniel +2 more
core +1 more source
DBC1 Regulates p53 Stability via Inhibition of CBP-Dependent p53 Polyubiquitination
Cell Reports, 2019 Summary: The control of p53 protein stability is critical to its tumor suppressor functions. The CREB binding protein (CBP) transcriptional co-activator co-operates with MDM2 to maintain normally low physiological p53 levels in cells via exclusively ...
Oluwatoyin E. Akande +6 more
doaj +1 more source
Distinct promoter elements mediate the co-operative effect of Brn-3a and p53 on the p21 promoter and their antagonism on the Bax promoter [PDF]
, 2002 Although the promoters of both the Bax and p21 genes are activated by p53, they differ in the effect on this activation of the POU family transcription factor Brn-3a. Thus, Brn-3a inhibits activation of the Bax promoter by p53 but enhances the ability of
Budhram-Mahadeo, VS +2 more
core
Upstream Targets in the p53 Pathway
, 2013 Small molecule reactivation of mutant forms of the tumour suppressor p53 or wild-type p53 function is an accepted strategy for the development of anticancer therapies.
McCarthy, AR, Lain, S
core +1 more source
Selective inhibition of microRNA accessibility by RBM38 is required for p53 activity [PDF]
, 2011 MicroRNAs (miRNAs) interact with 3'-untranslated regions of messenger RNAs to restrict expression of most protein-coding genes during normal development and cancer. RNA-binding proteins (RBPs) can control the biogenesis, stability and activity of miRNAs.
Horlings, HM +41 more
core +1 more source
Identification of CNOT1-CCR4-NOT as a suppressor of 53BP1-p53-p21 signaling
Cell ReportsSummary: Tumor suppressor p53 has inherent propensities to self-associate, which can lead to oncogenic p53 aggregation. The genome caretaker 53BP1 interacts with p53, forms DNA damage-associated condensates, and has been implicated in p53 activation ...
Antonio Galarreta +5 more
doaj +1 more source
Nerve Growth Factor Regulation of Transcription Factor p53 Activity
, 2007 p53 is recognized as a critical regulator of the cell cycle and apoptosis. Mounting evidence also suggests a role for p53 in the differentiation of several cell types including neuronal precursors. Using the pheochromocytoma PC12 cell model, we studied
Brynczka, Christopher
core